Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on Wednesday, September 28, 2022 at 1:00 PM ET.
A live webcast of the presentation will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, the event will remain archived on the Talaris website for 30 days.
About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.
Media Contact
Lisa Raffensperger
Ten Bridge Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
(617) 903-8783
Investor Contact
Chris Brinzey
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
(339) 970-2843
| Last Trade: | US$2.72 |
| Daily Volume: | 0 |
| Market Cap: | US$116.440M |
October 04, 2023 February 16, 2023 November 10, 2022 | |
UGE International develops, owns, and operates commercial and community solar projects in the United States and strategic markets abroad. Our distributed energy solutions deliver cheaper, cleaner energy to businesses and consumers...
CLICK TO LEARN MORE
Else Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...
CLICK TO LEARN MORE